

Naratuximab

Cat. No.:	HY-P99374
CAS No.:	1622327-39-2
Target:	ADC Antibody
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine ^[1] .
In Vitro	Naratuximab emtansine (IMGN529), an ADC comprised of DM1 linked to a humanized anti-CD37 antibody via the same linker used in Kadcyra. Naratuximab emtansine effectively combines the intrinsic proapoptotic and effector activities of its antibody component with the cytotoxic activity of the maytansinoid payload ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Stuart W Hicks, et al. The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models. *Neoplasia*. 2017 Sep;19(9):661-671.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA